Adial rises on positive FDA feedback for its late-stage alcohol disorder drug study

** Shares of drug developer Adial Pharmaceuticals ADIL.O rise 2.9% to 36 cents premarket

** Co says it has received positive feedback from the U.S. FDA on its late-stage trial testing an experimental treatment for alcohol use disorder

** ADIL says the meeting discussion focused on the late-stage study's design, including target population, clinical endpoints and dosing regimen; it adds the FDA supported ADIL's study design

** "Adial is implementing FDA recommendations consistent with the meeting outcomes, ensuring readiness to advance toward late-stage development," co says

** Co is testing its experimental treatment AD04 for alcohol use disorder in heavy-drinking patients

** Up to last close, stock down 65.4% YTD